Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy

Open access
Picaud, Sarah, Fedorov, Oleg, Thanasopoulou, Angeliki, Leonards, Katharina, Jones, Katherine, Meier, Julia, Olzscha, Heidi, Monteiro, Octovia, Martin, Sarah, Philpott, Martin, Tumber, Anthony, Filippakopoulos, Panagis, Yapp, Clarence, Wells, Christopher, Che, Ka Hing, Bannister, Andrew, Robson, Samuel, Kumar, Umesh, Parr, Nigel, Lee, Kevin, Lugo, Dave, Jeffrey, Philip, Taylor, Simon, Vecellio, Matteo L., Bountra, Chas, Brennan, Paul E., O'Mahony, Alison, Velichko, Sharlene, Müller, Susanne, Hay, Duncan, Daniels, Danette L., Urh, Marjeta, La Thangue, Nicholas B., Kouzarides, Tony, Prinjha, Rab, Schwaller, Jürg, Knapp, Stefan·2015·Cancer Research

Abstract

The histone acetyltransferases CBP/p300 are involved in recurrent leukemia-associated chromosomal translocations and are key regulators of cell growth. Therefore, efforts to generate inhibitors of CBP/p300 are of clinical value. We developed a specific and potent acetyl-lysine competitive protein–protein interaction inhibitor, I-CBP112, that targets the CBP/p300 bromodomains. Exposure of human and mouse leukemic cell lines to I-CBP112 resulted in substantially impaired colony formation and induced cellular differentiation without significant cytotoxicity. I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9+ acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. Interestingly, I-CBP112 increased the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin. Collectively, we report the development and preclinical evaluation of a novel, potent inhibitor targeting CBP/p300 bromodomains that impairs aberrant self-renewal of leukemic cells. The synergistic effects of I-CBP112 and current standard therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers. Cancer Res; 75(23); 5106–19. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-0236

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 229

Metadata

Authors
Picaud, S., Fedorov, O., Thanasopoulou, A., Leonards, K., Jones, K., Meier, J., Olzscha, H., Monteiro, O., Martin, S., Philpott, M., Tumber, A., Filippakopoulos, P., Yapp, C., Wells, C., Che, K. H., Bannister, A., Robson, S., Kumar, U., Parr, N., Lee, K., Lugo, D., Jeffrey, P., Taylor, S., Vecellio, M. L., Bountra, C., Brennan, P. E., O'Mahony, A., Velichko, S., Müller, S., Hay, D., Daniels, D. L., Urh, M., La Thangue, N. B., Kouzarides, T., Prinjha, R., Schwaller, J., & Knapp, S.
Venue
Cancer Research
Published
2015-11-30
Volume
75
Issue
23
Pages
5106-5119
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2137429553
Cited by
229
References
3
FWCI
11.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-0236
The paper
Picaud, S., Fedorov, O., Thanasopoulou, A., Leonards, K., Jones, K., Meier, J., Olzscha, H., Monteiro, O., Martin, S., Philpott, M., Tumber, A., Filippakopoulos, P., Yapp, C., Wells, C., Che, K. H., Bannister, A., Robson, S., Kumar, U., Parr, N., . . . Knapp, S. (2015). Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-0236

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.